Debasis Patnaik

US Patent:

20130102627, Apr 25, 2013

Filed:

Apr 8, 2011

Appl. No.:

13/639569

Inventors:

Jonathan Higgins - Chestnut Hill MA, US
Gregory D. Cuny - Cambridge MA, US
Marcie Glicksman - Winchester MA, US
Debasis Patnaik - Quincy MA, US
Maxime Robin - Marseille, FR
Ross L. Stein - Cambridge MA, US
Jun Xian - Sharon MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C07D 401/12
C07D 219/12
C07D 219/06

US Classification:

514297, 546103, 546106, 546104

Abstract:

The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.

US Patent:

20130231360, Sep 5, 2013

Filed:

Apr 21, 2011

Appl. No.:

13/639684

Inventors:

Jonathan Higgins - Chestnut Hill MA, US
Debasis Patnaik - Quincy MA, US
Natalia Ulyanova - Brookline MA, US
Ross L. Stein - Cambridge MA, US
Jun Xian - Sharon MA, US
Marcie Glicksman - Winchester MA, US
Gregory D. Cuny - Houston TX, US

Assignee:

THE BRIGHAM AND WOMEN S HOSPITAL, INC. - Boston MA

International Classification:

C07D 471/04
C07D 209/56

US Classification:

514287, 546 86, 514292, 548440, 514411, 546 65, 546 87

Abstract:

The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.

US Patent:

20130096129, Apr 18, 2013

Filed:

Jul 20, 2012

Appl. No.:

13/554670

Inventors:

Ling Pan - Charlestown MA, US
Stephen J. Haggarty - Dorchester MA, US
Debasis Patnaik - Quincy MA, US

International Classification:

C07C 219/28
C07D 487/04
C07D 405/12
C07D 307/52
C07D 409/12

US Classification:

514243, 549496, 514471, 549 60, 514444, 5483047, 514395, 544184, 564389, 514655

Abstract:

The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).

US Patent:

20200087236, Mar 19, 2020

Filed:

Jun 15, 2018

Appl. No.:

16/010030

Inventors:

- Cambridge MA, US
- Boston MA, US
Debasis PATNAIK - Weymouth MA, US

Assignee:

The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C07C 49/83
A61P 25/28
A61K 31/12
A61K 45/06
C07C 49/84
C07C 65/34
A61K 9/00

Abstract:

The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

US Patent:

20190211000, Jul 11, 2019

Filed:

Dec 21, 2018

Appl. No.:

16/231324

Inventors:

- Cambridge MA, US
- Boston MA, US
Stephen J. Haggarty - Gloucester MA, US
Debasis Patnaik - Weymouth MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C07D 405/12
C07D 307/40
C07D 411/12
C07C 217/58
C07C 219/28
C07D 409/12
C07D 307/52
C07D 487/04

Abstract:

The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).

US Patent:

20160280693, Sep 29, 2016

Filed:

Aug 25, 2015

Appl. No.:

14/834587

Inventors:

- Cambridge MA, US
- Boston MA, US
Stephen J. Haggarty - Gloucester MA, US
Debasis Patnaik - Weymouth MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C07D 405/12

Abstract:

The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).